Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 243

1.

Incidence and prevalence of MS in children: A population-based study in Ontario, Canada.

Marrie RA, O'Mahony J, Maxwell C, Ling V, Yeh EA, Arnold DL, Bar-Or A, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Neurology. 2018 Sep 26. pii: 10.1212/WNL.0000000000006395. doi: 10.1212/WNL.0000000000006395. [Epub ahead of print]

PMID:
30258022
2.

Physical activity and dentate gyrus volume in pediatric acquired demyelinating syndromes.

Longoni G, Brown RA, Aubert-Broche B, Grover SA, Branson HM, Fetco D, Bar-Or A, Marrie RA, Motl RW, Collins DL, Narayanan S, Arnold DL, Banwell B, Yeh EA.

Neurol Neuroimmunol Neuroinflamm. 2018 Sep 6;5(6):e499. doi: 10.1212/NXI.0000000000000499. eCollection 2018 Nov.

3.

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.

Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J; PARADIGMS Study Group.

N Engl J Med. 2018 Sep 13;379(11):1017-1027. doi: 10.1056/NEJMoa1800149.

PMID:
30207920
4.

Neuronal microRNA regulation in Experimental Autoimmune Encephalomyelitis.

Juźwik CA, Drake S, Lécuyer MA, Johnson RM, Morquette B, Zhang Y, Charabati M, Sagan SM, Bar-Or A, Prat A, Fournier AE.

Sci Rep. 2018 Sep 7;8(1):13437. doi: 10.1038/s41598-018-31542-y.

5.

MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study.

Fadda G, Brown RA, Longoni G, Castro DA, O'Mahony J, Verhey LH, Branson HM, Waters P, Bar-Or A, Marrie RA, Yeh EA, Narayanan S, Arnold DL, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Lancet Child Adolesc Health. 2018 Mar;2(3):191-204. doi: 10.1016/S2352-4642(18)30026-9. Epub 2018 Feb 1.

PMID:
30169254
6.

Pediatric-onset multiple sclerosis is associated with reduced parental health-related quality of life and family functioning.

O'Mahony J, Marrie RA, Laporte A, Bar-Or A, Yeh EA, Brown A, Dilenge ME, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Mult Scler. 2018 Aug 30:1352458518796676. doi: 10.1177/1352458518796676. [Epub ahead of print]

PMID:
30160208
7.

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L; RADIANCE Trial Investigators.

Mult Scler. 2018 Jul 25:1352458518789884. doi: 10.1177/1352458518789884. [Epub ahead of print]

PMID:
30043658
8.

Isotype-Switched Autoantibodies Are Necessary To Facilitate Central Nervous System Autoimmune Disease in Aicda-/- and Ung-/- Mice.

Galicia G, Lee DSW, Ramaglia V, Ward LA, Yam JY, Leung LYT, Li R, Handy M, Zhang J, Drohomyrecky PC, Lancaster E, Bar-Or A, Martin A, Gommerman JL.

J Immunol. 2018 Aug 15;201(4):1119-1130. doi: 10.4049/jimmunol.1700729. Epub 2018 Jul 6.

PMID:
29980612
9.

A framework for measurement and harmonization of pediatric multiple sclerosis etiologic research studies: The Pediatric MS Tool-Kit.

Magalhaes S, Banwell B, Bar-Or A, Fortier I, Hanwell HE, Lim M, Matt GE, Neuteboom RF, O'Riordan DL, Schneider PK, Pugliatti M, Shatenstein B, Tansey CM, Wassmer E, Wolfson C.

Mult Scler. 2018 Jun 1:1352458518783345. doi: 10.1177/1352458518783345. [Epub ahead of print]

PMID:
29932341
10.

Reassessing B cell contributions in multiple sclerosis.

Li R, Patterson KR, Bar-Or A.

Nat Immunol. 2018 Jun 20. doi: 10.1038/s41590-018-0135-x. [Epub ahead of print] Review.

PMID:
29925992
11.

Neuroimmune disorders of the central nervous system in children in the molecular era.

Wells E, Hacohen Y, Waldman A, Tillema JM, Soldatos A, Ances B, Benseler S, Bielekova B, Dale RC, Dalmau J, Gaillard W, Gorman M, Greenberg B, Hyslop A, Pardo CA, Tasker RC, Yeh EA, Bar-Or A, Pittock S, Vanderver A, Banwell B.

Nat Rev Neurol. 2018 Jul;14(7):433-445. doi: 10.1038/s41582-018-0024-9. Review.

PMID:
29925924
12.

Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis.

Darlington PJ, Stopnicki B, Touil T, Doucet JS, Fawaz L, Roberts ME, Boivin MN, Arbour N, Freedman MS, Atkins HL, Bar-Or A.

Front Immunol. 2018 May 7;9:834. doi: 10.3389/fimmu.2018.00834. eCollection 2018.

13.

Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI.

Maranzano J, Till C, Assemlal HE, Fonov V, Brown R, Araujo D, O'Mahony J, Yeh EA, Bar-Or A, Marrie RA, Collins L, Banwell B, Arnold DL, Narayanan S; Canadian Pediatric Demyelinating Disease Network.

Mult Scler. 2018 May 1:1352458518779952. doi: 10.1177/1352458518779952. [Epub ahead of print]

PMID:
29852831
14.

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.

Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, Derosier FJ, Lopez MC, Kavanagh ST, Miller AE, Sorensen PS.

Neurology. 2018 May 15;90(20):e1805-e1814. doi: 10.1212/WNL.0000000000005516. Epub 2018 Apr 25. Erratum in: Neurology. 2018 Sep 11;91(11):538.

15.

Human central nervous system astrocytes support survival and activation of B cells: implications for MS pathogenesis.

Touil H, Kobert A, Lebeurrier N, Rieger A, Saikali P, Lambert C, Fawaz L, Moore CS, Prat A, Gommerman J, Antel JP, Itoyama Y, Nakashima I, Bar-Or A; Canadian B Cell Team in MS.

J Neuroinflammation. 2018 Apr 19;15(1):114. doi: 10.1186/s12974-018-1136-2.

16.

The Multiple Roles of B Cells in Multiple Sclerosis and Their Implications in Multiple Sclerosis Therapies.

Li R, Bar-Or A.

Cold Spring Harb Perspect Med. 2018 Apr 16. pii: a029108. doi: 10.1101/cshperspect.a029108. [Epub ahead of print]

PMID:
29661809
17.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23.

PMID:
29576505
18.

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G.

Mult Scler J Exp Transl Clin. 2018 Mar 12;4(1):2055217318760642. doi: 10.1177/2055217318760642. eCollection 2018 Jan-Mar.

19.

The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk.

Lavery AM, Collins BN, Waldman AT, Hart CN, Bar-Or A, Marrie RA, Arnold D, O'Mahony J, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Mult Scler. 2018 Jan 1:1352458518757089. doi: 10.1177/1352458518757089. [Epub ahead of print]

PMID:
29393768
20.

MerTK-mediated regulation of myelin phagocytosis by macrophages generated from patients with MS.

Healy LM, Jang JH, Won SY, Lin YH, Touil H, Aljarallah S, Bar-Or A, Antel JP.

Neurol Neuroimmunol Neuroinflamm. 2017 Oct 16;4(6):e402. doi: 10.1212/NXI.0000000000000402. eCollection 2017 Nov.

21.

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.

Kappos L, Arnold DL, Bar-Or A, Camm AJ, Derfuss T, Sprenger T, Davies M, Piotrowska A, Ni P, Harada T.

Mult Scler. 2018 Oct;24(12):1605-1616. doi: 10.1177/1352458517728343. Epub 2017 Sep 15.

PMID:
28911260
22.

Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod.

Ghadiri M, Fitz-Gerald L, Rezk A, Li R, Nyirenda M, Haegert D, Giacomini PS, Bar-Or A, Antel J.

Mult Scler. 2017 Aug;23(9):1225-1232. doi: 10.1177/1352458517713147.

PMID:
28749311
23.

B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro.

Lisak RP, Nedelkoska L, Benjamins JA, Schalk D, Bealmear B, Touil H, Li R, Muirhead G, Bar-Or A.

J Neuroimmunol. 2017 Aug 15;309:88-99. doi: 10.1016/j.jneuroim.2017.05.004. Epub 2017 May 17.

PMID:
28601295
24.

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.

Fleischer V, Friedrich M, Rezk A, Bühler U, Witsch E, Uphaus T, Bittner S, Groppa S, Tackenberg B, Bar-Or A, Zipp F, Luessi F.

Mult Scler. 2018 Apr;24(5):632-641. doi: 10.1177/1352458517703799. Epub 2017 Apr 24.

PMID:
28436295
25.

Monophasic demyelination reduces brain growth in children.

Aubert-Broche B, Weier K, Longoni G, Fonov VS, Bar-Or A, Marrie RA, Yeh EA, Narayanan S, Arnold DL, Verhey LH, Banwell B, Collins DL; Canadian Pediatric Demyelinating Disease Network.

Neurology. 2017 May 2;88(18):1744-1750. doi: 10.1212/WNL.0000000000003884. Epub 2017 Apr 5.

26.

Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M, Morrison S, Reese Koc J, Gerson SL, Lazarus HM.

Mult Scler. 2018 Apr;24(4):501-511. doi: 10.1177/1352458517703802. Epub 2017 Apr 6.

PMID:
28381130
27.

Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis.

Ghadiri M, Rezk A, Li R, Evans A, Luessi F, Zipp F, Giacomini PS, Antel J, Bar-Or A.

Neurol Neuroimmunol Neuroinflamm. 2017 Mar 23;4(3):e340. doi: 10.1212/NXI.0000000000000340. eCollection 2017 May.

28.

White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders.

Longoni G, Brown RA, MomayyezSiahkal P, Elliott C, Narayanan S, Bar-Or A, Marrie RA, Yeh EA, Filippi M, Banwell B, Arnold DL; Canadian Pediatric Demyelinating Disease Network.

Brain. 2017 May 1;140(5):1300-1315. doi: 10.1093/brain/awx041.

PMID:
28334875
29.

Antibody-Independent Function of Human B Cells Contributes to Antifungal T Cell Responses.

Li R, Rezk A, Li H, Gommerman JL, Prat A, Bar-Or A; Canadian B Cells in MS Team.

J Immunol. 2017 Apr 15;198(8):3245-3254. doi: 10.4049/jimmunol.1601572. Epub 2017 Mar 8.

30.

Cyberinfrastructure for Open Science at the Montreal Neurological Institute.

Das S, Glatard T, Rogers C, Saigle J, Paiva S, MacIntyre L, Safi-Harab M, Rousseau ME, Stirling J, Khalili-Mahani N, MacFarlane D, Kostopoulos P, Rioux P, Madjar C, Lecours-Boucher X, Vanamala S, Adalat R, Mohaddes Z, Fonov VS, Milot S, Leppert I, Degroot C, Durcan TM, Campbell T, Moreau J, Dagher A, Collins DL, Karamchandani J, Bar-Or A, Fon EA, Hoge R, Baillet S, Rouleau G, Evans AC.

Front Neuroinform. 2017 Jan 6;10:53. doi: 10.3389/fninf.2016.00053. eCollection 2016.

31.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.

32.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

33.

Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.

Li R, Rezk A, Ghadiri M, Luessi F, Zipp F, Li H, Giacomini PS, Antel J, Bar-Or A.

J Immunol. 2017 Jan 15;198(2):691-698. doi: 10.4049/jimmunol.1601649. Epub 2016 Dec 14.

34.

Evaluating Soluble EMMPRIN as a Marker of Disease Activity in Multiple Sclerosis: Studies of Serum and Cerebrospinal Fluid.

Kaushik DK, Yong HY, Hahn JN, Silva C, Casha S, Hurlbert RJ, Jacques FH, Lisak R, Khan O, Ionete C, Larochelle C, Prat A, Bar-Or A, Yong VW.

PLoS One. 2016 Oct 11;11(10):e0163802. doi: 10.1371/journal.pone.0163802. eCollection 2016.

35.

Restoring immune tolerance in neuromyelitis optica: Part II.

Bar-Or A, Steinman L, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Smith TJ, Yeaman MR.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e277. doi: 10.1212/NXI.0000000000000277. eCollection 2016 Oct. Review.

36.

Restoring immune tolerance in neuromyelitis optica: Part I.

Steinman L, Bar-Or A, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Yeaman MR, Smith TJ.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e276. doi: 10.1212/NXI.0000000000000276. eCollection 2016 Oct. Review.

37.

Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases.

Bar-Or A, Hintzen RQ, Dale RC, Rostasy K, Brück W, Chitnis T.

Neurology. 2016 Aug 30;87(9 Suppl 2):S12-9. doi: 10.1212/WNL.0000000000002821. Review.

PMID:
27572856
38.

Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial.

Kappos L, Arnold DL, Bar-Or A, Camm J, Derfuss T, Kieseier BC, Sprenger T, Greenough K, Ni P, Harada T.

Lancet Neurol. 2016 Oct;15(11):1148-59. doi: 10.1016/S1474-4422(16)30192-2. Epub 2016 Aug 16.

PMID:
27543447
39.

Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment.

Bühler U, Fleischer V, Luessi F, Rezk A, Belikan P, Graetz C, Gollan R, Wolf C, Lutz J, Bar-Or A, Siffrin V, Zipp F.

Mult Scler. 2017 Apr;23(4):567-576. doi: 10.1177/1352458516658559. Epub 2016 Jul 21.

PMID:
27436357
40.

Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism.

Rozenberg A, Rezk A, Boivin MN, Darlington PJ, Nyirenda M, Li R, Jalili F, Winer R, Artsy EA, Uccelli A, Reese JS, Planchon SM, Cohen JA, Bar-Or A.

Stem Cells Transl Med. 2016 Nov;5(11):1506-1514. doi: 10.5966/sctm.2015-0243. Epub 2016 Jul 11.

41.

Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.

Atkins HL, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, Bence-Bruckler I, Birch P, Bredeson C, Chen J, Fergusson D, Halpenny M, Hamelin L, Huebsch L, Hutton B, Laneuville P, Lapierre Y, Lee H, Martin L, McDiarmid S, O'Connor P, Ramsay T, Sabloff M, Walker L, Freedman MS.

Lancet. 2016 Aug 6;388(10044):576-85. doi: 10.1016/S0140-6736(16)30169-6. Epub 2016 Jun 9.

PMID:
27291994
42.

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.

Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, MacManus DG, Yousry TA, Pozzilli C, Selmaj K, Sweetser MT, Zhang R, Yang M, Potts J, Novas M, Miller DH, Kurukulasuriya NC, Fox RJ, Phillips TJ.

Mult Scler. 2017 Feb;23(2):253-265. doi: 10.1177/1352458516649037. Epub 2016 Jul 11.

43.

Differential transcriptional response profiles in human myeloid cell populations.

Healy LM, Perron G, Won SY, Rao VTS, Guiot MC, Moore C, Bar-Or A, Antel JP.

Clin Immunol. 2018 Apr;189:63-74. doi: 10.1016/j.clim.2016.04.006. Epub 2016 Apr 16.

PMID:
27094466
44.

Central nervous system inflammation across the age span.

Bar-Or A, Antel JP.

Curr Opin Neurol. 2016 Jun;29(3):381-7. doi: 10.1097/WCO.0000000000000331. Review.

PMID:
27035901
45.

Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype.

Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, Thomas G, Zhou S, Wang Q, Elakkad A, Liebelt BD, Yaghi NK, Ezhilarasan R, Huang N, Weinberg JS, Prabhu SS, Rao G, Sawaya R, Langford LA, Bruner JM, Fuller GN, Bar-Or A, Li W, Colen RR, Curran MA, Bhat KP, Antel JP, Cooper LJ, Sulman EP, Heimberger AB.

JCI Insight. 2016;1(2). pii: e85841. Epub 2016 Feb 25.

46.

MerTK Is a Functional Regulator of Myelin Phagocytosis by Human Myeloid Cells.

Healy LM, Perron G, Won SY, Michell-Robinson MA, Rezk A, Ludwin SK, Moore CS, Hall JA, Bar-Or A, Antel JP.

J Immunol. 2016 Apr 15;196(8):3375-84. doi: 10.4049/jimmunol.1502562. Epub 2016 Mar 9.

47.

Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM.

Giovannoni G, Gold R, Kappos L, Arnold DL, Bar-Or A, Marantz JL, Yang M, Lee A.

Mult Scler J Exp Transl Clin. 2016 Feb 19;2:2055217316634111. doi: 10.1177/2055217316634111. eCollection 2016 Jan-Dec.

48.

Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.

Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, Cravets M, Olson A, Frohna PA, Selmaj KW; RADIANCE Study Group.

Lancet Neurol. 2016 Apr;15(4):373-81. doi: 10.1016/S1474-4422(16)00018-1. Epub 2016 Feb 12.

PMID:
26879276
49.

MicroRNA Expression Patterns in Human Astrocytes in Relation to Anatomical Location and Age.

Rao VT, Ludwin SK, Fuh SC, Sawaya R, Moore CS, Ho MK, Bedell BJ, Sarnat HB, Bar-Or A, Antel JP.

J Neuropathol Exp Neurol. 2016 Feb;75(2):156-66.

PMID:
26802178
50.

Meningeal Tertiary Lymphoid Tissues and Multiple Sclerosis: A Gathering Place for Diverse Types of Immune Cells during CNS Autoimmunity.

Pikor NB, Prat A, Bar-Or A, Gommerman JL.

Front Immunol. 2016 Jan 13;6:657. doi: 10.3389/fimmu.2015.00657. eCollection 2015. Review.

Supplemental Content

Loading ...
Support Center